Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Dong Y, Li X, Cheng J, et al. Drug development for Alzheimer’s disease: microglia induced neuroinflammation as a target? Int J Mol Sci. 2019;20(3):558.
2. Panza F, Lozupone M, Logroscino G, et al. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73–88.
3. Seo DO, Boros BD, Holtzman DM. The microbiome: a target for Alzheimer disease? Cell Res. 2019;29(10):779–80.
4. Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019;29(10):787–803.
5. Shanghai Green Valley Pharmaceuticals. Milestones of oligomannate (GV-971) development. 2019. https://www.greenvalleypharma.com. Accessed 28 Nov 2019.
Cited by
118 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献